期刊文献+

药源性循环免疫复合物检测方法的建立 被引量:2

Establishment of the detection method for drug-derived circulation immune complex
下载PDF
导出
摘要 目的通过重组人白介素1受体拮抗剂(rhIL-1Ra)的大鼠6mon重复给药毒性试验,建立临床前安全性评价中动物体内药源性循环免疫复合物(CIC)的检测方法,为临床CIC检测提供依据。方法从rhIL-1Ra免疫后的兔血清中纯化总IgG包被于酶标板上作为捕获抗体,SD大鼠抗rhIL-1Ra阳性血清与rhIL-1Ra以不同比例混和制成人工免疫复合物(AIC),通过双抗夹心ELISA检测AIC的效率来评价该方法有效性。定期采集连续26wk皮下注射rhIL-1Ra的大鼠血清并以上述方法检测CIC,同时用免疫组化法显示肾小球中的免疫复合物(IC)来验证该方法。结果双抗夹心ELISA法可显示AIC的数量差异,大鼠血清CIC显示出与给药时间一致的变化,并与肾小球中IC检测结果相印证。结论双抗夹心ELISA法可检测出动物因长期给予外源蛋白而产生的CIC,AIC则可作为该检测体系中的阳性对照。 Aim To establish a detection method for drug-derived circulation immune complex (CIC) , which might emerge in animal's blood during preclinical safety evaluation, with a case of recombinant human interleukin-1 receptor antagonist (rhIL-1Ra), and to provide reference to clinical trial with this method. Methods Total IgG was purified from serum of rhIL-1Ra-immunized rabbit and coated on microplate as capture antibody. A series of artificial immune complex (AIC) was prepared by mixing the serum from rhIL-1Ra-immunized SD rat and rhIL-I Ra with different ratios, and detected by a sandwich enzyme immunosorbent assay (ELISA) for effectivity evaluation of the method. Serum samples of SD rats injected (sc) with rhIL-1Ra for 26 weeks were collected periodically and CIC in the serum was detected by the method above. Meanwhile immune complex deposited in kidney was demonstrated by immune histochemistry. Resuits Variant quantities of AICs could be reflected by the sandwich ELISA. CIC in the rat serum appeared variance which consisted with the time of administration and proofed by IC in glomerular capillaries of kidney. Conclusion Sandwich ELISA can detect CIC due to repeated doses of foreign protein to animals with the positive control of AIC.
出处 《中国药理学通报》 CAS CSCD 北大核心 2009年第9期1248-1250,共3页 Chinese Pharmacological Bulletin
关键词 循环免疫复合物 重组人白介素1受体拮抗剂 SD大鼠 人工免疫复合物 双抗夹心ELISA法 免疫组化法 circulation immune complex recombinant interleukin-1 receptor antagonist SD rat artificial immune complex sandwich ELISA immune histochemistry
  • 相关文献

参考文献7

  • 1Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics [ J ]. Trends Biotechnol ,2006 ,24 :274 - 80.
  • 2Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals [ J ]. Nephrol Dial Transplant ,2006,21 ( Suppl 5 ) :9 -12.
  • 3吕秋军.生物技术药物免疫原性的评价及面临的挑战[J].中国新药杂志,2007,16(3):181-188. 被引量:24
  • 4Liebe V,Bruckmann M,Fischer K G,et al. Biological relevance of anti recombinant hirudin antibodies-resuhs from in vitro and in vivo studies [ J ]. Semin Thromb Hemost,2002,28 (5) :483 - 90.
  • 5苏汉文,詹玲屏.免疫复合物的检测方法[M]//朱立平,陈学清.免疫学常用实验方法.北京:人民军医出版社,2000:148-9.
  • 6孙妩弋,张玲玲,吴丽,汪倪萍,王华,岳莉,张运芳,魏伟.重组人白细胞介素-1受体拮抗剂对大鼠胶原性关节炎的治疗作用[J].中国药理学通报,2005,21(1):92-95. 被引量:9
  • 7Huub S. Bioequivalence and the immunogenicity of biopharmaceuticals [ J ]. Nat Rev Drug Discov Volume,2002,1:457 - 62.

二级参考文献30

  • 1李文敬 见:李文敬 孙希志 曹导源 苏厚恒主编.类风湿病[M].见:李文敬,孙希志,曹导源,苏厚恒主编.实用风湿病学 第2版[C].济南:山东科学技术出版社,2001.235-54.
  • 2Taylor PC. Anti-eytokines and cytokines in the treatment of rheumatoid arthritis[J]. Curt Pharm Des, 2003,9(14) : 1095 - 106.
  • 3Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases[ J]. Ann Rheum Dis,2002, 61(11) : 960-7.
  • 4Freeman BD, Buchman TG.Interleukin-I receptor antagonist as therapy for inflammatory disorders [ J ]. Expert Opin Biol Ther,2001, 1(2) : 301 -8.
  • 5Rubbert-Roth A, Perniok A. Treatment of patients with rheumatoid arthritis with the interleukin-I receptor antagonist anakinra(Kineret) [J]. Z Rheumatol, 2003, 62(4) :367 -77.
  • 6Chen Q, Wei W. Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats[ J ]. Int Immunopharmacol, 2003, 3(4) : 593 -608.
  • 7Fjuisawa H, Nishimara T, Motohaga A. Effect of actart on type Ⅱ collagen induced arthritis in mice [ J]. Arznein Forsh/Drug Res,1994, 44( l): 64-76.
  • 8Chowdhary RK, Ratkay LG, Neyndorff HC et al. The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice [ J ]. Clin Immunol Immunopathol, 1994,72(2) :255 -63.
  • 9Park SH, Min D J, Cho ML et al. Shift toward T helper 1 cytokines by type Ⅱ collagen-reactive T cells in patients with rheumatoid' arthritis[J]. Arthritis Rheum, 2001,44(3) :561 -9.
  • 10Arend WP. The balance between IL-I and IL-IRa in disease[J].Cytokine Growth Factor Rev, 2002, 13(4-5) : 323 -40.

共引文献31

同被引文献15

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部